RAC 2.92% $1.94 race oncology ltd

Ann: Preclinical & Clinical Programs Update, page-25

  1. 2,653 Posts.
    lightbulb Created with Sketch. 2404
    I wonder if RAC wanted to put this new collaboration into an ASX announcement but the ASX responded that it didn't qualify as news or if they thought it might be ramping?

    It feels like this article does provide significant insight into the progress of the other formulations of Zantrene and that it probably means there has been significant progress.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.